Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices

Significance Our study helps answer the question of how G protein-coupled receptors bind an extracellular ligand and relay this signal through its transmembrane helices into an intracellular signaling event. This has been the central thesis that G protein-coupled receptor structural studies have sought to address through static snapshots of the crystallized proteins. Our functional approach using CXC chemokine receptor 4 as a model complements these structures by identifying the dynamic atomic pathway from chemokine engagement to G protein coupling. The atomic-level mechanisms by which G protein-coupled receptors (GPCRs) transmit extracellular ligand binding events through their transmembrane helices to activate intracellular G proteins remain unclear. Using a comprehensive library of mutations covering all 352 residues of the GPCR CXC chemokine receptor 4 (CXCR4), we identified 41 amino acids that are required for signaling induced by the chemokine ligand CXCL12 (stromal cell-derived factor 1). CXCR4 variants with each of these mutations do not signal properly but remain folded, based on receptor surface trafficking, reactivity to conformationally sensitive monoclonal antibodies, and ligand binding. When visualized on the structure of CXCR4, the majority of these residues form a continuous intramolecular signaling chain through the transmembrane helices; this chain connects chemokine binding residues on the extracellular side of CXCR4 to G protein-coupling residues on its intracellular side. Integrated into a cohesive model of signal transmission, these CXCR4 residues cluster into five functional groups that mediate (i) chemokine engagement, (ii) signal initiation, (iii) signal propagation, (iv) microswitch activation, and (v) G protein coupling. Propagation of the signal passes through a “hydrophobic bridge” on helix VI that coordinates with nearly every known GPCR signaling motif. Our results agree with known conserved mechanisms of GPCR activation and significantly expand on understanding the structural principles of CXCR4 signaling.

[1]  Bas Vroling,et al.  GPCRdb: an information system for G protein-coupled receptors , 2015, Nucleic Acids Res..

[2]  Stephen M. Husbands,et al.  Structural insights into μ-opioid receptor activation , 2015, Nature.

[3]  Melinda S. Hanes,et al.  Dual Targeting of the Chemokine Receptors CXCR4 and ACKR3 with Novel Engineered Chemokines* , 2015, The Journal of Biological Chemistry.

[4]  Irina Kufareva,et al.  Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies , 2015, Immunology and cell biology.

[5]  Ruben Abagyan,et al.  Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine , 2015, Science.

[6]  R. Abagyan,et al.  Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: Molecular modeling and experimental validation , 2014, Proceedings of the National Academy of Sciences.

[7]  E. Davidson,et al.  A high‐throughput shotgun mutagenesis approach to mapping B‐cell antibody epitopes , 2014, Immunology.

[8]  Hualiang Jiang,et al.  Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.

[9]  D. Guo,et al.  Biased and Constitutive Signaling in the CC-chemokine Receptor CCR5 by Manipulating the Interface between Transmembrane Helices 6 and 7* , 2013, The Journal of Biological Chemistry.

[10]  Nouri Neamati,et al.  Small Molecule Inhibitors of CXCR4 , 2013, Theranostics.

[11]  R. Stevens,et al.  Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.

[12]  W. Boisvert,et al.  Leu1283.43 (L128) and Val2476.40 (V247) of CXCR1 Are Critical Amino Acid Residues for G Protein Coupling and Receptor Activation , 2012, PloS one.

[13]  Vadim Cherezov,et al.  Diversity and modularity of G protein-coupled receptor structures. , 2012, Trends in pharmacological sciences.

[14]  Xavier Deupi,et al.  Stabilized G protein binding site in the structure of constitutively active metarhodopsin-II , 2011, Proceedings of the National Academy of Sciences.

[15]  Xavier Deupi,et al.  Structural insights into agonist-induced activation of G-protein-coupled receptors. , 2011, Current opinion in structural biology.

[16]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[17]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[18]  Oliver P. Ernst,et al.  Crystal structure of metarhodopsin II , 2011, Nature.

[19]  Gebhard F. X. Schertler,et al.  The structural basis of agonist-induced activation in constitutively active rhodopsin , 2011, Nature.

[20]  J. Tesmer,et al.  Recognition in the Face of Diversity: Interactions of Heterotrimeric G proteins and G Protein-coupled Receptor (GPCR) Kinases with Activated GPCRs* , 2011, The Journal of Biological Chemistry.

[21]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[22]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[23]  P. Reeves,et al.  Highly conserved tyrosine stabilizes the active state of rhodopsin , 2010, Proceedings of the National Academy of Sciences.

[24]  Thomas M Frimurer,et al.  A Conserved Aromatic Lock for the Tryptophan Rotameric Switch in TM-VI of Seven-transmembrane Receptors* , 2009, The Journal of Biological Chemistry.

[25]  P. Scheerer,et al.  A G protein-coupled receptor at work: the rhodopsin model. , 2009, Trends in biochemical sciences.

[26]  Hideo Takahashi,et al.  Structural Basis of the Interaction between Chemokine Stromal Cell-derived Factor-1/CXCL12 and Its G-protein-coupled Receptor CXCR4* , 2009, The Journal of Biological Chemistry.

[27]  J. Rucker,et al.  Atomic-level mapping of antibody epitopes on a GPCR. , 2009, Journal of the American Chemical Society.

[28]  R. Wong,et al.  Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors , 2008, Molecular Pharmacology.

[29]  Xavier Deupi,et al.  Activation of G protein-coupled receptors. , 2007, Advances in protein chemistry.

[30]  C. Combs,et al.  Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions , 2006, Molecular Cancer Therapeutics.

[31]  Won-Tak Choi,et al.  Unique Ligand Binding Sites on CXCR4 Probed by a Chemical Biology Approach: Implications for the Design of Selective Human Immunodeficiency Virus Type 1 Inhibitors , 2005, Journal of Virology.

[32]  Won-Tak Choi,et al.  Distinct Functional Sites for Human Immunodeficiency Virus Type 1 and Stromal Cell-Derived Factor 1α on CXCR4 Transmembrane Helical Domains , 2005, Journal of Virology.

[33]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[34]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[35]  Francesca Fanelli,et al.  Mutagenesis and modelling of the alpha(1b)-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation. , 2002, Molecular pharmacology.

[36]  Zhaowen Luo,et al.  Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies* , 2001, The Journal of Biological Chemistry.

[37]  N. Heveker,et al.  Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities* , 2000, The Journal of Biological Chemistry.

[38]  Stephen C. Peiper,et al.  Identification of CXCR4 Domains That Support Coreceptor and Chemokine Receptor Functions , 1999, Journal of Virology.

[39]  B. Sykes,et al.  Solution structure and basis for functional activity of stromal cell‐derived factor‐1; dissociation of CXCR4 activation from binding and inhibition of HIV‐1 , 1997, The EMBO journal.

[40]  H Weinstein,et al.  Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor , 1997, The EMBO journal.

[41]  N. Heveker,et al.  Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity , 1997, Journal of virology.

[42]  H. Khorana,et al.  Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.